ImmuPharma PLC (UK) Performance
| IMM Stock | 3.40 0.16 4.49% |
ImmuPharma PLC holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.34, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, ImmuPharma PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding ImmuPharma PLC is expected to be smaller as well. Use ImmuPharma PLC maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to analyze future returns on ImmuPharma PLC.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuPharma PLC are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain technical and fundamental indicators, ImmuPharma PLC exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:1 | Ex Dividend Date 2021-12-14 | Last Split Date 2022-08-17 |
1 | ImmuPharma CEO Tim McCarthy shares latest developments with P140 platform, road ahead - Research Tree | 01/23/2025 |
2 | ImmuPharma hails oversubscribed 2.9m investment round - Proactive Investors USA | 02/12/2025 |
3 | ImmuPharma to present at Bio-Europe Spring in Milan - Investing.com | 03/14/2025 |
| Begin Period Cash Flow | 667.8 K |
ImmuPharma |
ImmuPharma PLC Relative Risk vs. Return Landscape
If you would invest 128.00 in ImmuPharma PLC on December 19, 2024 and sell it today you would earn a total of 212.00 from holding ImmuPharma PLC or generate 165.63% return on investment over 90 days. ImmuPharma PLC is generating 3.4254% of daily returns and assumes 26.3773% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than ImmuPharma on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ImmuPharma PLC Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmuPharma PLC's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImmuPharma PLC, and traders can use it to determine the average amount a ImmuPharma PLC's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1299
| Best Portfolio | Best Equity | |||
| Good Returns | IMM | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.38 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.43 actual daily | 68 68% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average ImmuPharma PLC is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmuPharma PLC by adding it to a well-diversified portfolio.
ImmuPharma PLC Fundamentals Growth
ImmuPharma Stock prices reflect investors' perceptions of the future prospects and financial health of ImmuPharma PLC, and ImmuPharma PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmuPharma Stock performance.
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 14.62 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Price To Book | 5.51 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | (69.96 K) | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
About ImmuPharma PLC Performance
By analyzing ImmuPharma PLC's fundamental ratios, stakeholders can gain valuable insights into ImmuPharma PLC's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImmuPharma PLC has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImmuPharma PLC has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ImmuPharma PLC is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about ImmuPharma PLC performance evaluation
Checking the ongoing alerts about ImmuPharma PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmuPharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmuPharma PLC is way too risky over 90 days horizon | |
| ImmuPharma PLC appears to be risky and price may revert if volatility continues | |
| ImmuPharma PLC has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (2.92 M) with loss before overhead, payroll, taxes, and interest of (69.96 K). | |
| ImmuPharma PLC generates negative cash flow from operations | |
| About 54.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmuPharma to present at Bio-Europe Spring in Milan - Investing.com |
- Analyzing ImmuPharma PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmuPharma PLC's stock is overvalued or undervalued compared to its peers.
- Examining ImmuPharma PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmuPharma PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmuPharma PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmuPharma PLC's stock. These opinions can provide insight into ImmuPharma PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImmuPharma Stock analysis
When running ImmuPharma PLC's price analysis, check to measure ImmuPharma PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuPharma PLC is operating at the current time. Most of ImmuPharma PLC's value examination focuses on studying past and present price action to predict the probability of ImmuPharma PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuPharma PLC's price. Additionally, you may evaluate how the addition of ImmuPharma PLC to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |